AMENDMENTS TO THE CLAIMS

This Listing of Claims will replace all prior versions, including listings, of claims in the application.

Claim 1 (Canceled).

Claim 2 (Currently Amended): The compound according to claim 45 <u>46</u>, wherein W is -NH-CH(E)-.

Claim 3 (Original): The compound according to claim 2, wherein -Z is a radical of the -Q-I-J-T type.

Claim 4 (Withdrawn): The compound according to claim 2, wherein -Z is a radical of the $-(CH_2)_s$ -X-P-I-J-T type.

Claim 5 (Withdrawn): The compound according to claim 4, wherein -X- is -O-.

Claim 6 (Withdrawn): The compound according to claim 4, wherein s is 2 and -X- is -NR4-.

Claim 7 (Withdrawn): The compound of claim 45, wherein W is -N(E)-CH2-CH2-.

Claim 8 (Withdrawn): The compound according to claim 7, wherein -Z is a radical of the -Q-I-J-T type.

Claim 9 (Withdrawn): The compound according to claim 7, wherein -Z is a radical of the - (CH₂)₈-X-P-I-J-T type.

Claim 10 (Withdrawn): The compound according to claim 9, wherein -X- is -O-.

Claim 11 (Withdrawn): The compound according to claim 9, wherein s is 2 and -X- is -NR4-.

Claim 12 (Currently Amended): The compound according to claim 45 46, wherein -A is an -OR1 type radical.

- Claim 13 (Currently Amended): The compound according to claim 45 46 selected from the group consisting of:
- (2S)-3-(4-benzyloxyphenyl)-2-[4-(4-butoxybenzyloxy)benzoylamino]propionic acid methyl ester;
- (2S)-3-(4-benzyloxyphenyl)-2-[4-(3-bromobenzyloxy)benzoylamino]propionic acid methyl ester;
- (2S)-3-(4-benzyloxyphenyl)-2-[4-(2-chlorobenzyloxy)benzoylamino]propionic acid methyl ester:
- (2S)-3-(4-benzyloxyphenyl)-2-[4-(2-fluorobenzyloxy)benzoylamino]propionic acid methyl ester;
- (2S)-3-(4-benzyloxyphenyl)-2-[4-(3-methylbenzyloxy)benzoylamino]propionic acid methyl ester;
- $\label{eq:continuous} (2S)-3-(4-benzyloxyphenyl)-2-[4-(3-trifluoromethylbenzyloxy)benzoylamino] propionic acid methyl ester;$
- (2S)-3-(4-benzyloxyphenyl)-2-[4-(2-methoxybenzyloxy)benzoylamino]propionic acid methyl ester;
- (2S)-3-(4-benzyloxyphenyl)-2-[4-(2-methylbenzyloxy)benzoylamino]propionic acid methyl ester:
- (2S)-3-(4-benzyloxyphenyl)-2-[4-(2-trifluoromethylbenzyloxy)benzoylamino]propionic acid methyl ester;

- (2S)-3-(4-benzyloxyphenyl)-2-[4-(2-o-tolylethoxy)benzoylamino]propionic acid methyl ester;
 - (2S)-3-(4-benzyloxyphenyl)-2-{4-[3-(4-
- propoxyphenoxy)propoxy]benzoylamino}propionic acid methyl ester;
- (2S)-3-(4-benzyloxyphenyl)-2-[4-(3-methoxybenzyloxy)benzoylamino]propionic acid methyl ester;
- (25)-3-(4-benzyloxyphenyl)-2-[4-(2-ethoxybenzyloxy)benzoylamino]propionic acid methyl ester;
- (2S)-3-(4-benzyloxyphenyl)-2-[4-(4-butylbenzyloxy)benzoylamino]propionic acid methyl ester;
 - (2S)-2-[4-(4-butylbenzyloxy)benzoylamino]-3-cyclohexylpropionic acid methyl ester;
- $\label{eq:continuous} (2S)-2-\{4-[2-(3-methylquinoxalin-2yloxy)ethoxy] benzoylamino}-3-phenylpropionic acid methyl ester;$
- (2S) 3 (4-benzyloxyphenyl) 2 [4 (2-pyridin-2-ylethoxy)benzoylamino] propionic acid methyl ester;
- (2S)-3-(4-benzyloxyphenyl)-2-{4-[2-(3-methylquinoxalin-2-yloxy)ethoxy]benzoylamino} propionic acid methyl ester;
- (2S)-3-(4-benzyloxyphenyl)-2-{4-[2-(pyridin-2-yloxy)ethoxy]benzoylamino}propionic acid methyl ester;
- (2S)-3-(4-benzyloxyphenyl)-2-{4-[2-(quinolin-8-yloxy)ethoxy]benzoylamino}propionic acid methyl ester;
- (2S)-3-(4-benzyloxyphenyl)-2-{4-[2-(quinolin-7-yloxy)ethoxy]benzoylamino} propionic acid methyl ester;
- (2S)-3-(4-benzyloxyphenyl)-2-{4-[2-(quinolin-2-yloxy)ethoxy]benzoylamino}propionic acid methyl ester:
- (2S)-3-(4-benzyloxyphenyl)-2-{4-[3-(3-methylquinoxalin-2yloxy)propoxy]benzoylamino}propionic acid methyl ester;

- (2S)-3-(4-bromophenyl)-2-{4-[2-(3-methylquinoxalin-2-
- yloxy)ethoxy]benzoylamino}propionic acid methyl ester;
 - (2S)-3-(4-fluorophenyl)-2-{4-[2-(3-methylquinoxalin-2-
- yloxy)ethoxy]benzoylamino}propionic acid methyl ester;
 - (2S)-3-(4-benzyloxyphenyl)-2-{4-[2-(3-methylquinoxalin-2-
- yloxy)ethoxy]benzoylamino}propionic acid ethyl ester;
- (2S)-3-(4-benzyloxyphenyl)-2-{4-[2-(3-methylquinoxalin-2-
- yloxy)ethoxy]benzoylamino}propionic acid isopropyl ester;
- (2S)-3-(4-benzyloxyphenyl)-2-{4-[2-(3-methylquinoxalin-2-
- yloxy)ethoxy]benzoylamino}propionic acid propyl ester;
 - (2S)-2-(4-benzyloxybenzoylamino)-3-(4-benzyloxyphenyl)propionic acid;
 - (2S)-2-[4-(3-benzyloxybenzyloxy)benzoylamino]-3-(4-benzyloxyphenyl)propionic acid;
 - 3-{(3-benzyloxybenzyl)-[4-(2-dibenzylaminoethoxy)benzoyl]amino}propionic acid;
 - 3-((3-benzyloxybenzyl)-{3-[2-(3-methylquinoxalin-2-
- vloxy)ethoxylbenzovl}amino)propionic acid;
 - 3-{(3-benzyloxybenzyl)-[4-(3-benzyloxybenzyloxy)benzoyl]amino}propionic acid;
 - 2-[4-(4-benzyloxybenzyloxy)benzoylamino]-3-(4-benzyloxyphenyl)propionic acid;
 - (2S)-2-[3-(4-benzyloxybenzyloxy)benzoylamino]-3-(4-benzyloxyphenyl)propionic acid;
 - 3-(4-benzyloxyphenyl)-2-[3-(biphenyl-4-ylmethoxy)benzoylaminolpropionic acid;
 - 2-[4-(3-benzyloxybenzyloxy)benzoylamino]-3-(4-bromophenyl)propionic acid;
 - 3-(4-benzyloxyphenyl)-2-[4-(4-butylbenzyloxy)benzoylamino]propionic acid;
 - 2-[4-(4-butylbenzyloxy)benzoylamino]-3-cyclohexylpropionic acid;
 - {(3-benzyloxybenzyl)-[4-(4-butylbenzyloxy)benzoyl]amino}acetic acid;
 - 3-{(3-benzyloxybenzyl)-[4-(4-butylbenzyloxy)benzoyllamino} propionic acid:
 - 3-(4-benzyloxyphenyl)-2-[4-(2-bromobenzyloxy)benzoylamino]propionic acid;
 - 3-(4-benzyloxyphenyl)-2-[4-(2-chlorobenzyloxy)benzoylamino]propionic acid;
 - 3-(4-benzyloxyphenyl)-2-[4-(2-methylbenzyloxy)benzoylamino]propionic acid;

3-(4-benzyloxyphenyl)-2-[4-(3-trifluoromethylbenzyloxy)benzoylamino]propionic acid;

and

3-(4-benzyloxyphenyl)-2-[4-(2-trifluoromethylbenzyloxy)benzoylamino]propionic acid.

Claim 14 (Currently Amended): A pharmaceutical composition comprising, as an active ingredient, a therapeutically effective amount of the compound according to claim 45 46 together with appropriate amounts of pharmaceutically acceptable excipients.

Claims 15-29 (Canceled).

Claim 30 (Withdrawn/Currently Amended): A method for the prophylactic and/or curative treatment of a condition mediated by PPARy in an animal including a human, comprising administering a therapeutically effective amount of a compound as defined in claim 45 46 together with an appropriate amount of pharmaceutically acceptable excipients.

Claim 31 (Withdrawn/Currently Amended): A method for the prophylactic and/or curative treatment of a condition mediated by both PPARy and PPARô in an animal including a human, comprising administering a therapeutically effective amount of a compound as defined in claim 45 46 together # with an appropriate amount of pharmaceutically acceptable excipients.

Claim 32 (Withdrawn): The method according to claim 30, wherein the administration is carried out orally, parenterally or topically.

Claim 33 (Withdrawn/Currently Amended): A method for the prophylactic and/or curative treatment of an animal including a human, suffering from a condition associated with metabolic diseases, comprising administering a therapeutically effective amount of a compound as defined in claim 45 46 together with an appropriate amount of pharmaceutically acceptable excipients.

Claim 34 (Withdrawn/Currently Amended): A method for the prophylactic and/or curative treatment of an animal including a human, suffering from a cardiovascular disease associated with metabolic syndrome, comprising administering a therapeutically effective amount of a compound as defined in claim 45 <u>46</u> together with an appropriate amount of pharmaceutically acceptable excipients.

Claim 35 (Withdrawn/Currently Amended): A method for the prophylactic and/or curative treatment of an animal, including a human, suffering from inflammation or an inflammatory process in general, comprising administering a therapeutically effective amount of a compound as defined in claim 45 46 together with an appropriate amount of pharmaceutically acceptable excipients.

Claim 36 (Withdrawn/Currently Amended): A method for the prophylactic and/or curative treatment of an animal, including a human, suffering from bone diseases comprising administering a therapeutically effective amount of a compound as defined in claim 45 46 together with an appropriate amount of pharmaceutically acceptable excipients.

Claim 37 (Withdrawn/Currently Amended): A method for the prophylactic and/or curative treatment of an animal, including a human, suffering from cancer, comprising administering a therapeutically effective amount of a compound as defined in claim 45 together r with 46 together with an appropriate amount of pharmaceutically acceptable excipients.

Claim 38 (Withdrawn/Currently Amended): A method for the prophylactic and/or curative treatment of an animal, including a human, suffering from skin wound healing or cutaneous disorders associated with an anomalous differentiation of epidermic cells, particularly the formation of keloids, comprising administering a therapeutically effective amount of a compound as defined in claim 45 46 together with an appropriate amount of pharmaceutically acceptable excipients.

Claim 39 (Withdrawn): The method of claim 33, wherein the metabolic disease is non-insulindependent diabetes mellitus (NIDDM).

Claim 40 (Withdrawn): The method of claim 33, wherein the metabolic disease is obesity.

Claim 41 (Withdrawn): The method of claim 33, wherein the metabolic disease is selected from hypercholesterolaemia and other lipid-mediated pathologies.

Claim 42 (Withdrawn): The method of claim 35, wherein the inflammatory process is selected from rheumatoid arthritis and atherosclerosis

Claim 43 (Withdrawn): The method of claim 35, wherein the inflammatory process is selected from psoriasis and intestinal inflammatory disease.

Claim 44 (Withdrawn): The method according to claim 31, wherein the administration is carried out orally, parenterally or topically.

Claim 45 (Canceled)

Claim 46 (New): A compound of formula (I),

$$Z \sim 0$$
 W A

 (Γ)

its stereoisomers and mixtures thereof, and addition salts of all of them, wherein the central benzene ring may be substituted in *meta-* or *para-* position and,

- -A is a radical selected from the group consisting of -OR1, -NR2OR1 and -NR2R3;
 wherein R1, R2 and R3 independently represent -H or -(C₁-C₄)-alkyl;
- -W- is a biradical -NH-CH(E)-, wherein E is a radical of the -G-I-J-K type where:
- -G-- is a bond or a -(CH2)1-4- biradical;
- -I- is a biradical of a cycle selected from the following groups:
 - a) cyclohexane optionally substituted by one or several radicals independently selected from -OH, -F, -Cl, -Br, (C₁-C₄)-alkanoyl, (C₁-C₄)-alkanoyloxy, (C₁-C₄)-alkyl optionally substituted by one or several -OH or -F, and (C₁-C₄)-alkoxyl optionally substituted by one or several -OH or -F; and
 - b) benzene substituted by one or several radicals independently selected from

 OH, -F, -Cl, -Br, (C₁-C₄)-alkyl optionally substituted by one or several -OH or

 F, and (C₁-C₄)-alkoxyl optionally substituted by one or several -OH or

 F:
- -J- is a bond or a biradical selected from the following groups:
 - a) -(CH₂)₁₋₄-alkylidene;
 - b) -O- and
 - c) -O-(C₁-C₄)- alkyl-;
- -K is a radical selected from the following groups:
 - a) -H;
 - b) (C1-C4)-alkyl; and

- c) phenyl or phenyl optionally substituted by one or several radicals independently selected from -OH, -F, -Cl, -Br, (C₁-C₄)-alkyl optionally substituted by one or several -OH or -F, and (C₁-C₄)-alkoxyl optionally substituted by one or several -OH or -F:
- -Z is a radical of -Q-I-J-T wherein
 - -Q- is a biradical -(CH₂)₁₋₃-;
 - -I- is benzene optionally substituted by one or several radicals independently selected from -OH, -F, -Cl, -Br, (C₁-C₄)-alkyl optionally substituted by one or several -OH or -F;
 and (C₁-C₄)-alkoxyl optionally substituted by one or several -OH or -F;
 - -J- is as defined above; and
 - -T is a radical selected from the following groups:
 - a.a) -H:
 - a,b) (C₁-C₄)-alkyl;
 - a.c) a radical from a five- or six-membered heterocycle containing from one to two heteroatoms selected from O, S and N, this heterocycle being optionally substituted by one or several radicals independently selected from -OH, -F, -Cl, -Br, (C₁-C₄)-alkyl optionally substituted by one or several -OH or -F, and (C₁-C₄)-alkoxyl optionally substituted by one or several -OH or -F; and
 - a.d) phenyl or a bicyclic system consisting of a benzene fused with a fiveor six-membered ring optionally containing from one to two heteroatoms selected from O, S and N, the phenyl or the bicyclic system being optionally substituted by one or several radicals independently selected from -OH, -F, -Cl, -Br, (C₁-C₄)-alkyl optionally substituted by one or several -OH or -F, and (C₁-C₄)-alkoxyl optionally substituted by one or several -OH or -F;

with the proviso that compound of formula (I) is neither of:

- 2-(4-benzyloxybenzoylamino)-3-phenylpropionic acid,
- 2-[4-(4-methoxybenzyloxy)benzoylamino]-3-phenylpropionic acid,
- 2-[4-(4-bromobenzyloxy)benzoylamino]-3-phenylpropionic acid,
- 2-(4-benzyloxybenzoylamino)-3-biphenyl-4-ylpropionic acid or
- 2-(4-benzyloxybenzoylamino)-3-(4'-trifluoromethoxybiphenyl-4-yl)propionic acid.